Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Assets (2016 - 2025)

Historic Return on Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 0.22%.

  • Cartesian Therapeutics' Return on Assets rose 3000.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.21% for FY2024, which is 7200.0% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Return on Assets stood at 0.22%, which was up 3000.0% from 0.2% recorded in Q2 2025.
  • Cartesian Therapeutics' Return on Assets' 5-year high stood at 0.15% during Q3 2022, with a 5-year trough of 1.18% in Q4 2023.
  • Moreover, its 5-year median value for Return on Assets was 0.2% (2025), whereas its average is 0.24%.
  • Per our database at Business Quant, Cartesian Therapeutics' Return on Assets tumbled by -13000bps in 2023 and then surged by 10900bps in 2024.
  • Cartesian Therapeutics' Return on Assets (Quarter) stood at 0.08% in 2021, then skyrocketed by 248bps to 0.12% in 2022, then plummeted by -1043bps to 1.18% in 2023, then soared by 93bps to 0.08% in 2024, then tumbled by -168bps to 0.22% in 2025.
  • Its last three reported values are 0.22% in Q3 2025, 0.2% for Q2 2025, and 0.1% during Q1 2025.